Omrix Biopharmaceuticals, Inc. Enters Into A Cooperative Research And Development Agreement (CRADA) With The National Institute of Allergy, Infectious Disease To Develop Antibody-Based Therapeutics For The Treatment Of Influenza

NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, today announced that it has signed a Cooperative Research and Development Agreement (“CRADA”) with the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (NIH), whereby the parties will perform collaborative research to develop new antibody-based therapeutics for the treatment of avian influenza.